Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.10
+7.10 (12.68%)
At close: Feb 11, 2026

TPEX:7871 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Jun '25 Dec '24 Dec '23
Net Income
-1,364-440.32268.21
Depreciation & Amortization
8.457.353.76
Loss (Gain) From Sale of Assets
-0.02-0.02-
Loss (Gain) on Equity Investments
0.310.31-
Stock-Based Compensation
2.914.021.71
Other Operating Activities
1,146226.55-372.17
Change in Accounts Receivable
-2.56-3.29-1.68
Change in Accounts Payable
6.61-33.664.98
Change in Unearned Revenue
---9.83
Change in Other Net Operating Assets
5.2-0.65-0.32
Operating Cash Flow
-197.85-239.7-105.33
Capital Expenditures
-8.07-9.97-0.22
Sale of Property, Plant & Equipment
0.020.02-
Investment in Securities
---0.29
Other Investing Activities
4.620.610.02
Investing Cash Flow
-8.43-9.34-0.49
Short-Term Debt Issued
-309.461.01
Total Debt Issued
634.6309.461.01
Long-Term Debt Repaid
--11-1.08
Net Debt Issued (Repaid)
623.7298.459.93
Issuance of Common Stock
47.381.651.91
Financing Cash Flow
671.08300.0561.83
Foreign Exchange Rate Adjustments
1.596.570.97
Net Cash Flow
466.3957.59-43.02
Free Cash Flow
-205.93-249.67-105.55
Free Cash Flow Margin
-20070.76%-31091.78%-410.76%
Free Cash Flow Per Share
-8.67-11.28-1.32
Cash Interest Paid
1.141.310.5
Levered Free Cash Flow
--176.75-
Unlevered Free Cash Flow
--175.93-
Change in Working Capital
9.24-37.59-6.85
Source: S&P Global Market Intelligence. Standard template. Financial Sources.